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Abstract 
 
Despite being an effective cancer prevention strategy, human papillomavirus (HPV) vaccination 
in Canada remain suboptimal. This study is the first to concurrently evaluate HPV vaccine 
knowledge, attitudes, and the decision-making stage of Canadian parents for their school-aged 
daughters and sons. Data were collected through an online survey from a nationally 
representative sample of Canadian parents of 9-16 year old children from August to September 
2016. Measures included socio-demographics, validated scales to assess HPV vaccine 
knowledge and attitudes (using the Health Belief Model), and parents’ HPV vaccination adoption 
stage using the Precaution Adoption Process Model (PAPM; six stages: unaware, unengaged, 
undecided, decided not, decided to, or vaccinated). 3,779 parents’ survey responses were 
analyzed (1,826 parents of sons and 1,953 parents of daughters). There was a significant 
association between child’s gender and PAPM stage of decision-making, with parents of boys 
more likely to report being in earlier PAPM stages. In multinomial logistic regression analyses 
parents of daughters (compared to sons), parents of older children, and parents with a health care 
provider recommendation had decreased odds of being in any earlier PAPM stage as compared to 
the last PAPM stage (i.e. vaccinated). Parents who were in the ‘decided not to vaccinate’ stage 
had significantly greater odds of reporting perceived vaccine harms, lack of confidence, risks, 
and vaccine conspiracy beliefs. Future research could use these findings to investigate 
theoretically informed interventions to specifically target subsets of the population with 
particular attention towards addressing knowledge gaps, perceived barriers, and concerns of 
parents.  
 
Keywords 
 
Human papillomavirus vaccination; vaccine uptake; vaccine intentions; vaccine hesitancy; 
determinants of health; gender; health behaviour change; Health Belief Model; Precaution 
Adoption Process Model 
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Highlights 
 
 Canadian parents report suboptimal HPV vaccination rates for their children 
 An integrated conceptual framework used the Health Belief Model (HBM) and 
Precaution Adoption Process Model (PAPM)  
 Parents of boys were more likely to report being in earlier PAPM stages  
 PAPM stages were associated with different psychosocial correlates  
 Tailored health messages could be developed to target individuals at different PAPM 
stages  
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Introduction 
 
Human papillomavirus (HPV) can cause a number of anogenital and oropharyngeal 
cancers in men and women.
1,2
 To prevent morbidity and mortality, three vaccines have been 
licensed and recommended for use.
3,4
 Currently, over 80 countries have implemented national 
HPV vaccination programs.
1,5,6
 In Canada, provinces and territories have implemented publicly 
funded school-based HPV vaccine programs. All Canadian jurisdictions implemented programs 
for girls, from 2007-2010.
7,8
 As of 2018, all jurisdictions also offer programs for boys in 
schools;
9
 however, the roll out of these programs (since 2013) has been staggered and HPV 
vaccination rates in Canada remain suboptimal.
3,8,10
  
Because HPV vaccination targets children,
3
 parental acceptance is critical to ensuring 
uptake. Previous research has indicated common themes associated with uptake, such as the 
importance of parents believing in the benefits of vaccination and perceiving few barriers.
11,12
 
Unsurprisingly, parents are less likely to vaccinate their children if they are not aware of, or do 
not know enough about, HPV vaccination. Parents are also less likely to vaccinate their child if 
they believe that HPV vaccination can cause harm, or that vaccination is not accessible or 
affordable.
13
 Furthermore, positive attitudes towards vaccines in general are related to HPV 
vaccine acceptance.
14,15
 Notably, a strong health care provider (HCP) recommendation 
significantly improves parental vaccine acceptance.
4,11,16
 Other social influences, including by a 
partner, family, friends, or online social network, can also influence parents’ decision.13,16-18    
It is likely that these factors have varying impact on parents depending on where they are 
in the decision-making process, which is obscured in much previous research investigating 
vaccination as a binary outcome (vaccinated or not). Literature on vaccine hesitancy highlights 
many reasons a parent may delay or refuse vaccination for their child.
19
 A theoretical stage-based 
model, the Precaution Adoption Process Model (PAPM), allows for a nuanced examination of 
which modifying factors and individual health beliefs are important for each stage of decision-
making (Figure 1).
20-22
 The PAPM identifies six stages involved in making a health decision and 
clarifies what factors lead individuals to move from one health behaviour decision-making stage 
to the next 
23
. A stage-based understanding of HPV vaccine decision-making is important for 
identifying the psychosocial correlates for each stage and how to best intervene for parents at 
different stages. Nevertheless, few studies have examined the stages of HPV vaccine decision-
 1 
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 5 
making in college students and parents of only boys,
16,24-26
 and no study has compared the stages 
of decision-making of parents of girls to parents of boys. Previous studies have found that 
college students and parents of boys were in the earliest stages of HPV vaccine decision-
making.
16,24-26
 Given HPV vaccine programs and policies have differentially targeted boys and 
girls, it is important to examine differences in decision-making stage between parents of girls and 
boys.  
This study will identify and compare parents’ stage of decision-making by gender for 
their school-aged daughters and sons, examine differences in parents’ HPV vaccine knowledge 
and attitudes by PAPM stage, and investigate the psychosocial correlates of parents’ PAPM 
stages.  
 
 
Methods 
 
Survey design and participants  
 
Details of the methodology are presented in the protocol paper.
20
 This study used a cross-
sectional design to collect self-reported online survey data from a national sample of Canadian 
parents. Data presented here were part of a larger two-wave protocol and were collected from 
August 17 to September 11, 2016 (i.e. Time one). All Canadian jurisdictions at this time had 
publicly funded, school-based HPV vaccination programs for girls but only three provinces (i.e. 
Alberta, Prince Edward Island, and Nova Scotia) had programs for boys.   
This study targeted parents and/or guardians (hereafter referred to as parents) of 9-16 
year-old boys and girls. Parents with more than one child were asked to answer the questionnaire 
in reference to the child who had the most recent birthday to ensure randomization. The online 
survey was offered in English and French (i.e. Canada's two official languages). Participants 
were recruited using, Leger-The Research Intelligence Group, which maintains a nationally 
representative panel of 400,000 Canadians.
27
 This study received Research Ethics Board 
approval from the Research Review Office, Integrated Health and Social Services University 
Network for West-Central Montreal (CODIM-FLP-16-219).
20
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 6 
Measures  
 
The dependent variable was parents’ PAPM stage, which categorizes parents’ stage of 
decision-making regarding HPV vaccination into six stages (Figure 1).
21
 
Potential psychosocial predictors of HPV vaccine decision-making included socio-
demographics, HCP recommendation, as well as validated scales to assess HPV and HPV 
vaccine knowledge, HPV vaccine attitudes, and general vaccine attitudes. HCP recommendation 
was assessed by asking parents, ‘did a health care provider (e.g. a doctor, pediatrician, or nurse) 
recommend that [child’s name] receive the HPV vaccine within the last 12 months?’.  Parents 
were only administered this question if they had answered affirmatively that they had seen a 
HCP and discussed their child receiving the HPV vaccine with a HCP.   
Two validated scales were used to measure parents’ knowledge of HPV and HPV 
vaccine.
28,29
 The 23-item HPV General Knowledge Scale (α=.94) and the 11-item HPV Vaccine 
Knowledge (VK) Scale (α=.88) (Appendix 1). To each item, respondents answered ‘true’, ‘false’, 
or ‘don’t know’, for which a total score was calculated based on correct answers (higher scores 
indicate greater knowledge on both scales). 
HPV vaccine attitudes were assessed using constructs from the Health Belief Model 
(HBM) including perceived benefits of, and barriers to, HPV vaccination; perceived severity of, 
and susceptibility to, HPV infection and disease; external influences prompting HPV vaccine 
uptake (i.e. cues to action), and the ability to exert change (i.e. self-efficacy). Sub-scales from the 
psychometrically validated HPV vaccination Attitudes and Beliefs Scale (HABS) were used to 
evaluate constructs from the HBM using a 7-point Likert-type rating scale ranging from 1 
(strongly disagree) to 7 (strongly agree).
29
 Sub-scales were evaluated for internal consistency 
using Cronbach’s α. HBM constructs, assessed using HABS subscales, included perceived 
susceptibility of child to HPV and its consequences (3 items, α=.92), perceived severity of HPV 
and its consequence (3 items, α=.84), perceived benefits of HPV vaccine (10 items, α=.94), 
perceived barriers to HPV vaccine (6 items to measure harms, α=.93; 4 items to measure 
accessibility, α=.79; and 3 items to measure affordability, α=.87), cues to action (8 items, α=.91), 
and self-efficacy (4 items α=.89) (Appendix 1).1 
                                                 
1
 All scales are subscales the HABS except self-efficacy, which is a construct of the HBM but 
was not included as a subscale in the HABS.  
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General vaccine attitudes were assessed using two psychometrically validated scales: the 
Vaccine Conspiracy Beliefs Scale (VCBS) and the Vaccine Hesitancy Scale (VHS).
14,15
 The 
VCBS has seven items assessed on a 7-point Likert-type rating scale (α=.95). The VHS was 
developed by the World Health Organization Sage Working Group on Vaccine Hesitancy,
30
 and 
psychometrically validated by our research group.
15
 The VHS was found to have two underlying 
factors (i.e. ‘lack of confidence’, α=.92; and ‘risks’, α=.64) and items are assessed on a 5-point 
Likert-type rating scale (Appendix 1).   
 
Analysis  
 
This study reports parents’ HPV vaccine decision-making in percentages based on the six 
PAPM stages. For assessing significant differences in PAPM stage based on child’s gender, a 
chi-square test was used. 
To examine differences between reported vaccine knowledge and attitudes by PAPM 
stage, one-way ANOVA and Tukey Honest Significant Difference (HSD) post-hoc tests were 
conducted.  
Multinomial logistic regression analyses were used to calculate the odds ratios of being in 
one of the first five PAPM stages compared to PAPM stage 6 (i.e. vaccinated, reference 
category). PAPM stage was the dependent variable. First, we conducted bivariate multinomial 
logistic regression analyses and estimated the associations for each independent variable 
individually. Subsequently, we performed multivariate multinomial logistic regression analyses 
by including 14 independent variables in a single model. In order to select variables that would 
ensure the most parsimonious and theory-driven multivariate model, variables were included 
based on attitudes predicted to be associated with behavioural change (according to the HBM) 
and significant modifying factors in the literature (see Figure 1).
16,31
 Odds ratios and 95% 
confidence intervals (CI) were calculated. To assess multicollinearity of the multivariate 
multinomial logistic regression models, the Variation Inflation Factor (VIF) was calculated for 
all predictors. Model fit diagnostics were reported based on following criteria: (a) Cox-Snell R
2
, 
(b) Cragg-Uhler R
2
, and (c) McFadden R
2
.  
Statistical analyses were performed using IBM SPSS V.23 and R 3.3.2. 
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Results 
 
Sample Demographics  
 
A total of 4,606 parents completed the survey.  The response rate, calculated based on 
completion by participants who initiated the questionnaire (N=6,789) was 67.9%. Overall, 827 
(18.0%) participants were excluded as these participants were detected to be inattentive or 
unmotivated respondents based on data cleaning (i.e. the use of two bogus items and index of 
psychometric synonyms).
20
 Sociodemographic characteristics for the final sample (N=3,779) are 
presented in Table 1. At the time of data collection, only 7% were parents of boys living in 
provinces where there was a publicly funded HPV vaccine program for boys available (n = 252) 
and fewer still would have been eligible for the program depending upon their child’s age. 
 
Identifying Canadian parents’ stage of decision-making by child’s gender  
 
Table 2 shows the numbers of parents of boys and parents of girls across the six PAPM 
stages. HPV vaccine uptake of Canadian children was low, with only 801 (41.0%) parents of 
girls reporting that their daughters were vaccinated and only 160 (8.8%) parents of boys 
reporting that their sons were vaccinated. There was a significant and large association between 
child’s gender and PAPM stage of decision making (χ2(5)=735.25, p<.001, φc=.44) with parents 
of boys more likely to be in earlier stages.
32
  
 
Comparison of knowledge and attitudes for HPV vaccine PAPM stages 
 
One-way ANOVA found that there was a significant effect of PAPM stage on all vaccine 
knowledge and attitude scales (Table 3). The greatest effect sizes were for cues to action, 
benefits, and barriers-harms. 
Post hoc analyses found that knowledge (both HPV vaccine knowledge and HPV general 
knowledge) was significantly lower for PAPM stages 1-3 (unaware, unengaged, and undecided) 
compared to later PAPM stages. In addition, parents who were unaware reported significantly 
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 9 
lower perceived vaccine affordability compared to parents who were unengaged and undecided, 
while parents who were unaware and unengaged reported significantly lower perceived harms 
and VHS-risk compared to parents who were undecided.  
Parents who decided not to vaccinate (Stage 4) significantly differed from all other PAPM 
stages on all scales except barriers-not accessible, self-efficacy, and knowledge scales (VK and 
GK); however, on these four scales, parents who decided not to vaccinate responded similarly to 
parents who decided to vaccinate or already vaccinated their child (Stages 5 and 6). 
Parents who decided to vaccinate their child (Stage 5) reported significantly higher perceived 
benefits, greater perceived barriers of accessibility and affordability, and fewer cues to action 
compared to those who already vaccinated their child (Stage 6). 
 
Examination of correlates of PAPM stage  
 
The bivariate and multivariate multinomial logistic regression analyses of parents’ PAPM 
stage can be found in Tables 4 and 5, respectively. Appendix 2 contains exploratory analyses of 
additional variables as well as all analyses conducted separately for parents of boys and girls. All 
earlier stages of PAPM were compared to the reference group (Stage 6-Vaccinated). 
 
Bivariate multinomial logistic regression 
Parents of daughters, older children, and parents with a HCP recommendation had 
decreased odds of being in any earlier PAPM stage as compared to the last PAPM stage (i.e. 
vaccinated). Higher HPV vaccine knowledge was significantly associated with decreased odds of 
being unaware, unengaged, undecided, or decided to vaccinate. 
Parents who had decided not to vaccinate their child had significantly stronger vaccine 
conspiracy beliefs (OR=3.10; 95% CI 2.78;3.46), lack of confidence in vaccines (OR=9.21; 95% 
CI 7.50;11.31), and higher perception of vaccine risks (OR=5.19; 95% CI 4.38;6.16) compared 
to parents who vaccinated their child.  
Parents living in provinces with HPV vaccination programs for boys had significantly 
lower odds of being unaware (OR=0.34; 95% CI 0.24;0.48), unengaged (OR=0.49; 95% CI 
0.34;0.70), or undecided (OR=0.50; 95% CI 0.37;0.67). Further analysis by child’s gender 
indicated that this effect was not significant in the model examining parents of girls; however, 
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 10 
parents of boys living in provinces with HPV vaccine funding for boys had significantly lower 
odds of being in any earlier PAPM stage compared to vaccinated (Tables B4 and B7). 
 
Multivariate multinomial logistic regression 
Parents of daughters and older children had significantly decreased odds of reporting that 
their child was in any earlier PAPM stage compared to vaccinated . Parents answering the survey 
in French had lower odds of being unengaged (OR=0.67; 95% CI 0.47;0.97), undecided 
(OR=0.61; 95% CI 0.44;0.84) and decided to vaccinate (OR=0.51; 95% CI 0.38;0.67).  
Parents who received a HCP recommendation for HPV vaccination had lower odds of 
being unaware (OR=0.04; 95% CI 0.01;0.16), unengaged (OR=0.21; 95% CI 0.10;0.43), 
undecided (OR=0.55; 95% CI 0.36;0.84), and decided not to vaccinate (OR=0.30; 95% CI 
0.15;0.61). There was no significant difference between the decided to vaccinate and vaccinated 
groups. Higher HPV vaccine knowledge was significantly associated with decreased odds of 
being unaware (OR=0.75; 95% CI 0.71;0.79), unengaged (OR=0.86; 95% CI 0.81;0.91), and 
increased odds of having decided not to vaccinate (OR=1.12; 95% CI 1.04;1.22).  
A higher perception of susceptibility and severity were only significantly associated with 
decreased odds of being in the stage decided not to vaccinate (OR=0.68; 95% CI 0.55;0.84 and 
OR=0.66; 95% CI 0.54;0.80). Higher perception of the benefits of vaccination was significantly 
associated with increased odds of being unaware (OR=1.89; 95% CI 1.48;2.41), unengaged 
(OR=1.62; 95% CI 1.26;2.08), undecided (OR=1.40; 95% CI 1.12;1.74) and decided to vaccinate 
(OR=2.10; 95% CI 1.72;2.55), and decreased odds of being decided not to vaccinate (OR=0.60; 
95% CI 0.45;0.81).  
Compared to those who vaccinated their child, parents in all other stages had significantly 
increased odds of reporting greater barriers (including affordability, accessibility, and perceived 
harms). However, perceived accessibility of parents who vaccinated their children did not differ 
significantly with parents who were undecided, decided not to vaccinate their child, or decided to 
vaccinate their child. Of note, parents who had a higher score on perceived harms had higher 
odds of being in Stage 4 (decided not to vaccinate) (OR=3.50; 95% CI 2.85;4.28). Greater 
perceived influence of others (cues to action) was associated with lower odds of being in any of 
the earlier stages (compared to vaccinated) (OR range of 0.20 to 0.51).  
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Discussion 
 
This study examined six distinct stages of HPV vaccine decision-making using the 
PAPM framework in a national survey of Canadian parents of 9-16 year-old boys and girls. Only 
41.0% of girls and 8.8% of boys were in the final PAPM stage (Stage 6-Vaccinated). This is a 
lower proportion of vaccinated children than reported by other Canadian studies,
3,33
 which may 
be due to this study’s design, which included data from jurisdictions without male HPV 
vaccination programs during data collection, relied on parental report of vaccination status, and 
evaluated a larger age range of children (including children before they were offered the HPV 
vaccine in funded school-based programs).  
In a 2014  study using the PAPM to examine Canadian parents of boys, the majority of 
parents were unaware of HPV vaccination for their sons (Stage 1, 57.0%), while exceptionally 
few had decided to vaccinate their son (Stage 5, 5.0%) or had sons who had received the HPV 
vaccine (Stage 6, 1.1%).
16
 Data from the present study indicates that two years later and with two 
additional Canadian jurisdictions with male HPV vaccine programs (Alberta and Nova Scotia), 
fewer parents were unaware (25.6%), and more parents had decided to vaccinate (19.1%) or 
already vaccinated (8.8%) their son (Table 2). By comparison, a survey of parents of boys 
conducted around the same time in the UK (when there was no funded program for boys) found 
that 46.8% were unaware.
34
 This emphasizes the importance of publicly funded vaccine 
programs and the associated educational campaigns in increasing awareness and uptake.
35-37
  
Two further studies have used the PAPM to evaluate HPV vaccine decision-making.
26,38
 
Though these studies were conducted in college students, both found males to be 
overwhelmingly unaware or unengaged (90% or 85.7%, respectively),
26,38
 and Barnard et al. also 
found females to be predominantly in these stages (62.9%).
38
 
The present study was unique in evaluating PAPM stages for both parents of girls and 
boys. The literature has primarily focused on parents of girls,
35,37-44
 with none using the PAPM. 
We found a significant association between child’s gender and PAPM stage of decision-making, 
with parents of boys more likely to be in earlier PAPM stages, a finding similar to results from 
other studies.
35,37,39-41
 
Multinomial analyses highlighted some important correlates across all PAPM stages as 
well as some correlates that are particularly important for specific stages. Overall, this study 
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found that parents of daughters (compared to sons), of older children, and parents with a HCP 
recommendation had decreased odds of being in any earlier PAPM stage as compared to the last 
PAPM stage (i.e. vaccinated). The importance of a HCP recommendation in making the decision 
regarding HPV vaccination is a well-established finding.
11,12,16,35,37,41,45
 This study contributes to 
the literature by highlighting that a HCP recommendation is a significant and important 
differential factor between parents who are ‘hesitant’ (unengaged, undecided, and decided not; 
Stages 2-4) and ‘acceptors’ (decided to vaccinate and vaccinated; Stages 5-6), but not a 
significant differential factors between acceptor groups (Stages 5 and 6). This suggests that while 
a HCP recommendation may increase the likelihood that a parent accepts HPV vaccination; a 
HCP recommendation alone may not be sufficient to move parents from deciding to vaccinate 
their child (Stage 5) to having vaccinated their child (Stage 6).  
The relationship between knowledge and uptake has previously yielded mixed results (as 
high and low knowledge have been associated with vaccination).
12,46
 Application of the PAPM 
model shows that low HPV vaccine knowledge is an important correlate of early stages of 
decision-making (as compared to vaccinated). Interestingly, in the multivariate analysis parents 
who had decided not to vaccinate their child had significantly higher HPV vaccine knowledge 
than parents who vaccinated their child. Accordingly, education interventions alone may not be 
sufficient for HPV vaccination.  
In line with previous research, this study found perceived benefits, barriers-harms, and 
cues to action were key correlates of PAPM stage.
12
 Previous research using a binary outcome 
has reported mixed findings regarding the relationship between HPV vaccination with perceived 
severity and susceptibility of HPV infection and associated disease.
12,31
 By using a nuanced 
framework of decision-making, this study highlights that, when taking all other variables into 
account, susceptibility and severity were not significant correlates of earlier PAPM stages except 
for the ‘decided not to vaccinate’ stage (Stage 4). Future research should use these findings to 
investigate theoretically informed interventions to specifically target subsets of the population 
(by child’s gender and decision-making stage), with particular attention towards addressing 
knowledge gaps, perceived barriers, and concerns of parents.  
Interestingly, parents of boys (but not parents of girls) living in provinces with HPV 
vaccination programs for boys had significantly lower odds of being in early PAPM stages, 
emphasizing the importance of publicly funded HPV vaccine programs for boys. 
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Study strengths and limitations  
 
This study is unique in examining and comparing HPV vaccine decision-making in 
Canadian parents of boys and girls using two well-established theoretical frameworks (i.e. the 
HBM and the PAPM), which captures decision-making in a nuanced and precise way. This is the 
first study to use the PAPM to evaluate HPV vaccine decision-making in parents of girls and 
boys. Strengths of the study also include a large sample size, data cleaning techniques that 
eliminated careless responders, and a nationally representative sample.
20
 This study’s 
questionnaire benefited from the use of intelligent programming to personalize survey items, 
administration in either English or French, avoiding any missing data, the use of 
psychometrically validated scales, and the randomization of items within scales to reduce the 
possibility of an order effect.
20
   
This study is not without limitations. The cross-sectional design makes it impossible to 
determine causality. Although we had a reasonable response rate (67.9%), there remains the 
potential that there were similarities between non-responders that could influence the 
representativeness of the sample. Furthermore, although the sample was generally representative 
of the Canadian population, it was slightly wealthier, more educated, and White (as compared to 
the 2016 Census).
47
 This study was also not able to recruit many participants living in Canada’s 
territories, due to constraints in Leger’s panel. Future research is needed to replicate this study’s 
conceptual framework and findings to specifically investigate HPV vaccination in disadvantaged 
populations, as well as in other countries or in cross-country comparisons.  
It is also possible that the measurement of HCP recommendation in this study overlooked 
parents who were recommended the vaccine by a HCP but had not seen or discussed the HPV 
vaccine with a HCP (e.g. via a letter that was sent home). Moreover, the scope of variables 
assessed is limited, there are other familial, sociological, environmental, and communication 
factors that were not included. Specifically, future research should consider the impact of having 
an older child who was eligible for, or received, the HPV vaccine. Future research should also 
further examine the impact of publicly funded HPV vaccination programs on parents’ decision-
making. 
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Conclusions  
 
HPV vaccination remains low in Canada. Using a stage-based model of decision-making, 
this study found that only a quarter of parents were in the final PAPM stage. Parents of daughters, 
older children, and those with a HCP recommendation had decreased odds of being in any earlier 
PAPM stage. Individual health beliefs as well as cues to action were key correlates of PAPM 
stage overall; however, the combinations and importance of correlates varied by PAPM stage and 
child’s gender. These findings indicate that it may be important for future interventions to target 
and tailor health messaging for different groups depending on their stage of decision-making.  
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Figure 1. An integrated conceptual framework of HPV vaccination  
 
 
 
Note. The PAPM, as applied to HPV vaccination, identifies individuals along six stages of decision-making: 1) 
unaware of the vaccine (“I was unaware that the HPV vaccine could be given to CHILD*”); 2) unengaged in the 
decision to vaccinate their child (“I have never thought about vaccinating CHILD* against HPV”); 3) undecided 
about whether to vaccinate their child (“I am undecided about vaccinating CHILD* against HPV”); 4) decided not to 
act (i.e. decided not to vaccinate their child, “I have decided I DO NOT want to vaccinate CHILD* against HPV”); 
5) decided to act (i.e. decided to vaccinate their child, “I have decided I DO want to vaccinate CHILD* against 
HPV”); and 6) acted (i.e. vaccinated their child, “CHILD* has already received the HPV vaccine”). *To increase the 
personalization of this questionnaire, intelligent programming allowed for each question with “CHILD” to 
specifically include their child’s name.  
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Table 1. Sample Characteristic (N = 3,779) 
 
Participant Characteristics N (%) 
Parent’s gender  
Men 
Women 
 
1,311 (34.69) 
2,468 (65.31) 
Parent’s age  
Range (years) 
Mean (SD) 
 
18-81 
43.51 (6.86) 
Language in which parents answered the survey 
     English 
     French 
 
2,801 (74.12) 
978 (25.88) 
Marital status  
Single/Separated/divorced/widowed 
Married/common law 
 
760 (20.11) 
3,019 (79.89) 
Parent’s level of education  
Elementary or high school 
Trade technical or university 
 
659 (17.44) 
3,120 (82.56) 
Parent’s employment status 
Employed 
Not employed 
 
3,057 (80.89) 
722 (19.11) 
Born in Canada 
Yes 
No 
 
3,214 (85.05) 
565 (14.95) 
Parent’s ethnicity 
White 
Other 
 
3,224 (85.31) 
555 (14.69) 
Parent’s religion 
Any religious affiliation 
No religious affiliation 
 
2,493 (65.97) 
1,286 (34.03) 
Household income  
<100 K 
≥ 100 K 
Prefer not to answer 
 
1,973 (52.21) 
1,409 (37.28) 
397 (10.51) 
Child’s gender  
Boys (sons) 
Girls (daughters) 
 
1,826 (48.32) 
1,953 (51.68) 
Child’s age  
Range (years) 
Mean (SD) 
 
9-16 
12.58 (2.31) 
Child’s school’s religion 
No affiliation 
Any religious affiliation 
 
2,821 (74.65) 
958 (25.35) 
Child’s school’s language 
English 
French and Other 
 
2,647 (70.04) 
1,132 (29.96) 
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Province with funded HPV vaccination for boys  
No 
Yes 
 
3,225  (85.34) 
554 (14.66) 
Size of city 
<100K 
≥ 100K 
 
1,799  (47.61) 
1,980 (52.39) 
Number of children in the family 
1 
2 
≥3 
 
868  (22.97) 
1,747 (46.23) 
1,164 (30.80) 
Child’s sexual orientation 
Heterosexual  
Other 
 
3,301  (87.35) 
478 (12.65) 
HCP recommendation 
No 
Yes 
 
3,346  (88.54) 
433 (11.46) 
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Table 2. Parents’ PAPM stage by child’s gender  
 
PAPM Stage 
Parents of girls  
(n = 1,953) 
Parents of boys 
 (n = 1,826) 
Test of 
proportions girls 
versus boys 
All parents 
(N = 3,779) 
 n (%) n (%) 95% CI N (%) 
Stage 1-
Unaware 
 
136 (7.0) 468 (25.6) -20.96; -16.37 604 (16.0) 
Stage 2-
Unengaged 
 
97 (5.0) 298 (16.3) -13.30; -9.40 395 (10.5) 
Stage 3-
Undecided 
 
291 (14.9) 389 (21.3) -8.86; -3.94 680 (18.0) 
Stage 4-
Decided NOT 
191 (9.8) 162 (8.9) -0.95; 2.76 353 (9.3) 
Stage 5-
Decided YES 
 
437 (22.4) 349 (19.1) 0.68; 5.85 786 (20.8) 
Stage 6-
Vaccinated 
 
801 (41.0) 160 (8.8) 29.71; 34.79 961 (25.4) 
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      Table 3. Comparison of parents’ vaccine knowledge and attitudes by PAPM stage 
 
Scale Total 
N = 3,779 
Stage 1-
Unaware 
n = 604 
Stage 2-
Unengaged 
n = 395 
Stage 3-
Undecided 
n = 680 
Stage 4-
Decided NOT 
n = 353 
Stage 5-
Decided YES 
n= 786 
Stage 6-
Vaccinated 
n = 961 
ANOVA F  
test-
statistic  
Effect 
size (ω) 
 M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)   
HPV Vaccine Knowledge 
HPV General 
Knowledge 
 
12.79 (6.07) 8.53 (6.51) 
a
 11.34 (5.97) 
b
 12.95 (5.77) 
c
 14.88 (5.45) 
d
 14.33 (5.39) 
d
 13.93 (5.32) 
d
 101.32 0.34 
 
 
HPV Vaccine 
Knowledge 
 
6.01 (2.92) 3.76 (3.07) 
a
 4.85 (2.97) 
b
 5.89 (2.75) 
c
 6.88 (2.55) 
d
 6.74 (2.48) 
d
 7.06 (2.37) 
d
 149.95 0.41 
 
HPV-specific HBM attitudes  
Susceptibility  4.93 (1.38) 4.73 (1.16) 
a 
4.61 (1.16) 
a,b 
4.50 (1.08) 
b 
3.00 (1.37)
 c
 5.65 (1.09)
 d
 5.64 (1.05)
 d
 382.00 0.58 
 
Severity  5.91 (1.08) 5.84 (1.08)
 a
 5.82 (1.05) 
a
 5.83 (1.06) 
a
 5.18 (1.39) 
b
 6.15 (0.94) 
c
 6.13 (0.96) 
c
 53.11 0.25 
 
Benefits  4.90 (1.14) 4.87 (0.95) 
a
 4.75 (0.93) 
a,b
 4.58 (0.86)
 b
 3.10 (1.06) 
c
 5.57 (0.86) 
d
 5.33 (0.91) 
e
 421.15 0.60 
 
Barriers-not 
affordable  
3.61 (1.70) 4.70 (1.33) 
a
 4.35 (1.37) 
b
 4.16 (1.52) 
b
 3.09 (1.56) 
c
 3.78 (1.64) 
d
 2.30 (1.31) 
e
 275.65 0.52 
 
Barriers-not 
accessible  
2.85 (1.15) 3.57 (0.92) 
a
 3.35 (0.98) 
a,b
 3.18 (1.02) 
b
 2.86 (1.16) 
c
 2.65 (1.12) 
c
 2.15 (0.99) 
d
 188.42 0.45 
 
Barriers-harms  3.54 (1.42) 3.74 (1.07) 
a
 3.82 (1.10) 
a
 4.18 (1.12) 
b
 5.50 (1.21) 
c
 2.85 (1.17) 
d
 2.68 (1.12) 
d
 433.92 0.60 
 
Cues to action  4.62 (1.16) 4.14 (0.88) 
a
 3.98 (0.88) 
a
 4.06 (0.79) 
a
 3.43 (1.02) 
b
 5.11 (0.94) 
c
 5.61 (0.85) 
d
 554.38 0.65 
 
Self efficacy  6.00 (1.01) 5.63 (1.10) 
a
 5.65 (1.09) 
a
 5.67 (1.03) 
a
 6.29 (1.00) 
b
 6.27 (0.82) 
b
 6.28 (0.83) 
b
 79.45 0.31 
 
General Vaccine Attitudes  
VCBS  3.23 (1.44) 3.46 (1.36) 
a
 3.40 (1.38) 
a
 3.56 (1.35) 
a
 4.70 (1.35) 
b
 2.66 (1.31) 
c
 2.73 (1.21) 
c
 160.04 0.42 
 
VHS-Lack of 
Confidence  
1.98 (0.72) 2.04 (0.66) 
a
 2.07 (0.64) 
a
 2.13 (0.65) 
a
 2.84 (0.91) 
b
 1.69 (0.57) 
c
 1.74 (0.54) 
c
 196.69 0.45 
 
VHS-Risks  3.07 (0.95) 3.15 (0.85) 
a
 3.14 (0.86) 
a
 3.38 (0.87) 
b
 3.90 (0.83) 
c
 2.75 (0.94) 
d
 2.74 (0.85) 
d
 132.25 0.38 
 
Note. All skewness and kurtosis are less than 2. VHS scales are measured 1-5; all other scales are measured 1-7. All one-way independent groups ANOVA were 
significant (all p < .001). Effect sizes (ω) are presented for each ANOVA analysis. Post hoc tests were conducted using Tukey HSD. For each scale, groups that were not 
significantly different (p < .01) from each other in post hoc tests are in the same group (notated using a superscript, e.g. 
a
).
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       Table 4. Bivariate multinomial logistic regression analysis of parents’ PAPM stage (N = 3,779) 
 
Variables Stage 1-Unaware 
OR  
(95% CI) 
n = 604 
Stage 2-Unengaged 
OR  
(95% CI) 
n = 395 
Stage 3-Undecided 
OR  
(95% CI) 
n = 680 
Stage 4-Decided 
NOT 
OR  
(95% CI) 
n = 353 
Stage 5-Decided YES 
OR  
(95% CI) 
n= 786 
Child’s gender 
  Male 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Female 0.06*** (0.04; 0.07) 0.07*** (0.05; 0.09) 0.15*** (0.12; 0.19) 0.24*** (0.18; 0.31) 0.25*** (0.20; 0.31) 
Child’s age (One-year increase) 0.73*** (0.69; 0.76) 0.80*** (0.76; 0.84) 0.76*** (0.73; 0.79) 0.81*** (0.76; 0.85)  0.71*** (0.68; 0.75) 
Language parents answered the survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  1.26 (1.02; 1.57) 0.65* (0.49; 0.85) 0.56*** (0.45; 0.71) 0.87 (0.67; 1.14) 0.48*** (0.38; 0.60) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 0.64* (0.48; 0.86) 0.61* (0.44; 0.85) 0.75 (0.56; 0.99) 0.90 (0.62; 1.31) 0.71 (0.54; 0.94) 
HCP recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Yes 0.01*** (0.01; 0.05) 0.09*** (0.04; 0.17) 0.32*** (0.24; 0.45) 0.43*** (0.29; 0.62) 0.74 (0.58; 0.95) 
HPV Vaccine knowledge  
(One-unit increase)  
0.66*** (0.64; 0.69) 0.74*** (0.71; 0.78) 0.84*** (0.81; 0.87) 0.97 (0.92; 1.02) 0.95* (0.91; 0.98) 
Susceptibility (One-unit increase) 0.47*** (0.43; 0.52) 0.43*** (0.39; 0.48) 0.40*** (0.36; 0.44) 0.16*** (0.14; 0.18) 1.01 (0.92; 1.10) 
Severity (One-unit increase) 0.75*** (0.68; 0.83) 0.74*** (0.66; 0.82) 0.74*** (0.67; 0.82) 0.48*** (0.43; 0.54) 1.03 (0.93; 1.14) 
Benefits (One-unit increase) 0.57*** (0.50; 0.63) 0.49*** (0.42; 0.56) 0.39*** (0.35; 0.44) 0.08*** (0.07; 0.1)  1.36*** (1.22; 1.51) 
Barriers-Affordability (One-unit increase) 3.03*** (2.78; 3.30) 2.59*** (2.37; 2.83) 2.38*** (2.20; 2.57) 1.49*** (1.37; 1.63) 2.02*** (1.88; 2.17) 
Barriers-Accessibility (One-unit increase) 3.74*** (3.34; 4.20) 3.02*** (2.67; 3.42) 2.60*** (2.34; 2.88) 1.95*** (1.73; 2.19) 1.60*** (1.46; 1.76) 
Barriers-Harms (One-unit increase) 2.22*** (2.02; 2.44) 2.36*** (2.11; 2.63) 3.12*** (2.82; 3.45) 8.85***(7.60; 10.31) 1.14* (1.05; 1.24) 
Cues to action (One-unit increase) 0.15*** (0.13; 0.17) 0.12*** (0.10; 0.14) 0.13*** (0.11; 0.15) 0.06*** (0.05; 0.07) 0.55*** (0.50; 0.62) 
Self-Efficacy (One-unit increase) 0.50*** (0.45; 0.56) 0.51*** (0.45; 0.57) 0.51*** (0.46; 0.57) 1.02 (0.88; 1.19) 0.99 (0.88; 1.11) 
Vaccine conspiracy beliefs (One-unit 
increase) 
1.51*** (1.40; 1.64) 1.47*** (1.34; 1.60) 1.60*** (1.48; 1.73) 3.10*** (2.78; 3.46) 0.96 (0.89; 1.03) 
Hesitancy-Lack of Confidence (One-unit 
increase) 
2.34*(1.97; 2.79) 2.49*** (2.05; 3.03) 2.86*** (2.42; 3.38) 9.21***(7.50; 11.31) 0.86 (0.72; 1.02) 
Hesitancy-Risks  (One-unit increase) 1.69*** (1.50; 1.90) 1.65*** (1.44; 1.89) 2.31*** (2.05; 2.61) 5.19*** (4.38; 6.16) 1.01 (0.91; 1.12) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 961). Bold integers indicates significant OR at p < .05. *p < .01, **p < .001, ***p < .0001. 
(reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval. HCP = health care provider.  
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          Table 5. Multivariate multinomial logistic regression analysis of parents’ PAPM stage (N = 3,779) 
 
Variables  Stage 1-Unaware 
AOR (95% CI) 
n = 604 
Stage 2-Unengaged 
AOR (95% CI) 
n = 395 
Stage 3-Undecided 
AOR (95% CI) 
n = 680 
Stage 4-Decided 
NOT  
AOR (95% CI) 
n = 353 
Stage 5-Decided 
YES  
AOR (95% CI) 
n= 786 
Child’s gender 
  Male 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Female 0.15*** (0.11; 0.21) 0.15*** (0.11; 0.22) 0.33*** (0.24; 0.45) 0.36*** (0.23; 0.57) 0.49*** (0.37; 0.65) 
Child’s age (One-year increase) 0.63*** (0.59; 0.67)  0.69*** (0.65; 0.74) 0.68*** (0.64; 0.73) 0.80*** (0.74; 0.88)  0.64*** (0.60; 0.67) 
Language parents answered the survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  1.21 (0.87; 1.69) 0.67 (0.47; 0.97) 0.61* (0.44; 0.84) 0.91 (0.58; 1.43) 0.51*** (0.38; 0.67) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 1.37 (0.91; 2.06) 1.28 (0.84; 1.96) 1.62 (1.10; 2.39) 1.16 (0.65; 2.05) 1.31 (0.93; 1.84) 
HCP recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Yes 0.04*** (0.01; 0.16) 0.21*** (0.10; 0.43) 0.55* (0.36; 0.84) 0.30** (0.15; 0.61) 0.89 (0.66; 1.20) 
HPV Vaccine knowledge  
(One-unit increase)  
0.75*** (0.71;0.79) 0.86*** (0.81; 0.91) 0.98 (0.93; 1.04) 1.12* (1.04; 1.22) 0.96 (0.91; 1.01) 
Susceptibility (One-unit increase) 0.97 (0.81; 1.17) 0.98 (0.81; 1.18) 0.89 (0.75; 1.05) 0.68** (0.55; 0.84) 1.06 (0.91; 1.23) 
Severity (One-unit increase) 1.06 (0.91; 1.25) 1.06 (0.90; 1.25) 1.08 (0.93; 1.25) 0.66*** (0.54; 0.80) 1.02 (0.89; 1.16) 
Benefits (One-unit increase) 1.89*** (1.48; 2.41) 1.62** (1.26; 2.08) 1.40* (1.12; 1.74) 0.60** (0.45; 0.81)  2.10*** (1.72; 2.55) 
Barriers-Affordability (One-unit increase) 1.99*** (1.76; 2.24) 1.62*** (1.43; 1.84) 1.70*** (1.52; 1.90) 1.22 (1.03; 1.43) 1.68*** (1.53; 1.84) 
Barriers-Accessibility (One-unit increase) 1.50*** (1.27; 1.78) 1.26 (1.05; 1.50) 1.10 (0.94; 1.29) 1.07 (0.85; 1.34) 1.14 (0.99; 1.31) 
Barriers-Harms (One-unit increase) 1.53*** (1.31; 1.78) 1.68*** (1.43; 1.97) 2.19*** (1.90; 2.52) 3.50*** (2.85; 4.28)  1.15 (1.01; 1.30) 
Cues to action (One-unit increase) 0.27*** (0.22; 0.34) 0.20*** (0.16; 0.25) 0.24*** (0.19; 0.29) 0.21*** (0.16; 0.28) 0.51*** (0.43; 0.61) 
Self-Efficacy (One-unit increase) 1.10 (0.91; 1.33) 1.16 (0.96; 1.40) 1.11 (0.93; 1.32) 1.87*** (1.49; 2.35) 1.24 (1.04; 1.48) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 961). Bold integers indicates significant AOR at p < .05. *p < .01, **p < .001, ***p < .0001. 
Cox-Snell R
2
 = 0.72. Cragg Uhler R
2
 = 0.74. McFadden R
2
 = 0.37. (reference) = reference category. AOR = adjusted odds ratio. 95% CI = 95% confidence interval. 
HCP = health care provider.  
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Appendices 
 
 
Appendix A. Validated scales 
 
Please find all the psychometrically validated scales that were used in this study in the tables below (Tables A1-A3). We hope 
that the inclusion of these scales in this appendix will facilitate replication, further validation, and exploration of these scales in future 
research. 
 
 
Table A1. HPV and HPV vaccine knowledge  
 
HPV General Knowledge Scale 
 Question  True/ False/ Don’t Know 
1 HPV is very rare  F 
2 HPV always has visible signs or symptoms F 
3 HPV can cause cervical cancer T 
4 HPV can be transmitted through genital skin-to-skin contact T 
5 There are many types of HPV T 
6 HPV can cause HIV/AIDS F 
7 HPV can be passed on during sexual intercourse T 
8 HPV can cause genital warts T 
9 Men cannot get HPV F 
10 Using condoms reduces the chances of HPV transmission T 
11 HPV can be cured with antibiotics F 
12 Having many sexual partners increases the risk of getting HPV T 
13 Most sexually active people will get HPV at some point in their lives T 
14 A person could have HPV for many years without knowing it T 
15 Having sex at an early age increases the risk of getting HPV T 
16 HPV can cause anal cancer T 
17 HPV is a bacterial infection F 
18 HPV can be transmitted through oral sex T 
19 HPV can cause cancer of the penis T 
20 HPV can be transmitted through anal sex T 
21 HPV infections always lead to health problems F 
22 HPV can cause oral cancer T 
23 A person with no symptoms cannot transmit the HPV infection F 
HPV Vaccine Knowledge Scale 
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 Question  True/ False/ Don’t Know 
1 The HPV vaccine requires at least 2 doses  T 
2 The HPV vaccines offers protection against all sexually transmitted infections  F 
3 The HPV vaccines are most effective if given to people who’ve never had sex T 
4 Someone who has had the HPV vaccine cannot develop cervical cancer F 
5 The HPV vaccines offer protection against most cervical cancers T 
6 The HPV vaccine offers protection against genital warts T 
7 Girls who have had an HPV vaccine do not need a Pap test when they are older  F 
8 The HPV vaccine protects you from every type of HPV F 
9 You can cure HPV by getting the HPV vaccine  F 
10 The HPV vaccine is approved and recommended by Health Canada for females aged 9-45 years T 
11 The HPV vaccine is approved and recommended by Health Canada for males aged 9-26 years T 
Source: Perez, S., Tatar, O., Ostini, R., Shapiro, G. K., Waller, J., Zimet, G., & Rosberger, Z. (2016). Extending and validating a human papillomavirus (HPV) 
knowledge measure in a national sample of Canadian parents of boys. Preventive Medicine, 91, 43-49. doi: 10.1016/j.ypmed.2016.07.017 
 
Note. As recommended by the authors, two items from the original GK scale administration (‘HPV usually doesn’t need any treatment’ and ‘HPV can cause 
herpes’) were deleted from this study’s because the psychometric evaluation found that when removed the reliability of the scale improved. Further, in this 
study’s administration of the VK Scale, ‘vaccines’ was changed to ‘vaccine’ to make the measure consistently in the singular.  Slight adaptations were also made 
to ensure the items were gender-neutral (rather than directed at parents of males only) and updated based on policy recommendations and current generation 
vaccines. 
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Table A2. HPV-specific vaccine attitudes  
 
Severity (HABS ‘Perceived Threat’) 
1 …it would be serious if [CHILD] contracted HPV later in life 
 2 …it would be serious if [CHILD] contracted genital warts later in life 
3 …it would be serious if [CHILD] contracted an HPV-related cancer later in life 
 
Susceptibility (HABS ‘Risk’) 
1 …without the HPV vaccine, [CHILD] would be at risk of getting HPV later in life. 
2 …without the HPV vaccine, [CHILD] would be at risk of getting genital warts later in life. 
3 …without the HPV vaccine, [CHILD] would be at risk of getting an HPV-related cancer later in life. 
Benefits (HABS ‘Benefits’) 
1 …the HPV vaccine has many benefits 
2 …the HPV vaccine will protect [CHILD]’s sexual health 
3 …the HPV vaccine works well 
4 …the HPV vaccine is effective in preventing HPV 
5 …the HPV vaccine is effective in preventing genital warts 
6 
…vaccinating [CHILD] against HPV may be a good thing to do for [CHILD]’s health 
…vaccinating [CHILD] against HPV was a good thing to do for [CHILD]’s health* 
7 
… vaccinating [CHILD] against HPV would give me peace of mind about [CHILD]’s sexual health 
…having vaccinated [CHILD] against HPV gives me peace of mind about [CHILD]’s sexual health* 
8 …the HPV vaccine is effective in preventing HPV-related cancers 
9 
…vaccinating [CHILD] against HPV would protect [CHILD]’s current/future partner from getting infected with HPV 
…having vaccinated [CHILD] against HPV protects [CHILD]’s current/future partner from getting infected* 
10 
…getting [CHILD] the HPV vaccine would protect [CHILD]’s current/future partner against cancer 
…having gotten [CHILD] the HPV vaccine protects [CHILD]’s current/future partner against cancer* 
Barriers Accessibility (HABS ‘Accessibility’) 
1 
…it is hard to find a clinic that would be easy to access for getting the HPV vaccine for [CHILD]  
…it was hard to find a clinic that was easy to access for getting the HPV vaccine for [CHILD] *  
2 …it is hard to find a provider or clinic where I would not have to wait a long time to get an appointment for [CHILD] to get vaccinated  
3 
…dealing with getting the HPV vaccine for [CHILD] would be simple 
…dealing with getting the HPV vaccine for [CHILD] was simple* 
4 
…the process of actually getting the HPV vaccine for [CHILD] would be easy 
…the process of actually getting the HPV vaccine for [CHILD] was easy* 
Barriers Affordability (HABS ‘Affordability’) 
1 
…the HPV vaccine is too expensive 
…the HPV vaccine was too expensive* 
2 
…my/our insurance does not cover enough of the cost of the HPV vaccine for [CHILD] 
…my/our insurance did not cover enough of the cost of the HPV vaccine for [CHILD] * 
3 …the HPV vaccine costs more than I can afford 
 4 
…the HPV vaccine cost more than I could afford* 
Barriers Harms (HABS ‘Harms’) 
1 …the HPV vaccine is being pushed to make money for pharmaceutical companies 
2 
…giving [CHILD] the HPV vaccine would be like performing an experiment on [CHILD] 
…giving [CHILD] the HPV vaccine was like performing an experiment on [CHILD]* 
3 …the HPV vaccine may lead to long-term health problems 
4 …the HPV vaccine is too new 
5 …there has not been enough research done on the HPV vaccine 
6 …the HPV vaccine is unsafe 
Cues to Action (HABS ‘Influence’) 
1 …other parents in my community are getting their children the HPV vaccine 
2 …my friends are getting their children vaccinated with the HPV vaccine 
3 …other children around [CHILD]'s age are getting vaccinated with the HPV vaccine 
4 
…it is expected of me that I should vaccinate [CHILD] against HPV 
…it was expected of me that I should vaccinate [CHILD] against HPV* 
5 
…most of my friends think vaccinating [CHILD] against HPV is a good idea 
…most of my friends think vaccinating [CHILD] against HPV was a good idea* 
6 
…my [CHILD]'s other parent believes we should get the HPV vaccine for [CHILD] 
…my [CHILD]'s other parent believes in having gotten the HPV vaccine for [CHILD] * 
7 …doctors/health care providers believe vaccinating [CHILD] against HPV is a good idea 
8 
…my family thinks it is a good idea to vaccinate [CHILD] against HPV 
…my family thinks it was a good idea to vaccinate [CHILD] against HPV* 
Self Efficacy + 
1 …competent to make decisions about the vaccines [CHILD] receives  
2 …competent to make decisions about [CHILD]’s health  
3 …confident in making the decision about whether [CHILD] receives the HPV vaccine  
4 …capable to make the decision about whether [CHILD] receives the HPV vaccine  
Source: Perez S, Shapiro GK, Tatar O, Joyal-Desmarais K, Rosberger Z. Development and validation of the human papillomavirus attitudes and beliefs scale in a 
National Canadian sample. Sexually Transmitted Diseases 2016; 43(10): 626-32. 
 
Note. All items were modified to make them gender neutral (i.e. [CHILD] instead of ‘my son’).  Signifies reverse coded items. * Signifies that this item has two 
possible stem phrasing depending on PAPM stage (PAPM Group 1-5, vs. 6). + items were developed to measure ‘self-efficacy’ (i.e. items not measured by Perez 
et al. 2016). 
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Table A3. General vaccine attitudes  
 
Vaccine Conspiracy Beliefs Scale 
1 
1 Vaccine safety data is often fabricated 
2  Negative vaccination effects are covered up  * 
3 Pharmaceutical companies cover up the dangers of vaccines 
4 People are deceived about vaccine efficacy 
5 Vaccine efficacy data is often fabricated 
6 People are deceived about vaccine safety 
7 The government is trying to cover up the link between vaccines and autism. 
Vaccine Hesitancy Scale  -Lack of Confidence 
2 
1 Childhood vaccines are important for my child’s health (R) 
2  Childhood vaccines are effective (R) 
3 Having my child vaccinated is important for the health of others in my community (R) 
4 All childhood vaccines offered by the government program in my community are beneficial (R) 
5 The information I receive about vaccines from the vaccine program is reliable and trustworthy (R) 
6 Getting vaccines is a good way to protect my child/children from disease (R) 
7 Generally I do what my doctor or health care provider recommends about vaccines for my child/children (R) 
 
Vaccine Hesitancy Scale  -Risks 
2 
1 I am concerned about serious adverse effects of vaccines 
2 New vaccines carry more risks than older vaccines  
Sources: 
1 
Shapiro GK, Holding A, Perez S, Amsel R, Rosberger Z. Validation of the vaccine conspiracy belief scale. Papillomavirus Research 2016; 2: 167-72. 
2 
Shapiro GK, Tatar O, Dube E, et al. The Vaccine Hesitancy Scale: Psychometric properties and validation. Vaccine 2018; 36: 545-52. 
 
Note. * One item from the original scale (‘immunizing children is harmful and this fact is covered up’) was modified slightly in this study’s administration (to 
‘negative vaccination effects are covered up’) as this was a double-barrelled question.  
(R) Indicates items that were reverse coded. 
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Appendix B. Additional multinomial logistic regression analyses of parents’ PAPM stage 
 
 
1. Exploratory bivariate multinomial logistic regression analyses of parents of boys and girls (N = 3,779)  
 
Exploratory bivariate multinomial logistic regression analyses were conducted to examine the relationship between additional 
variables of interest and parents’ PAPM stage (Table B1). 
 
 
Table B1. Bivariate multinomial logistic regression analysis of parents’ PAPM stage (N = 3,779) for additional variables 
 
Variables Stage 1-Unaware 
OR (95% CI) 
n = 604 
Stage 2-Unengaged 
OR (95% CI) 
n = 395 
Stage 3-Undecided 
OR (95% CI) 
n = 680 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 353 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 786 
Parent’s gender 
  Male 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Female 0.58*** (0.47; 0.71) 0.49*** (0.38; 0.62) 0.81 (0.66; 1.00) 1.28 (0.97; 1.68) 0.84 (0.68; 1.03) 
Parent’s age (one year increase) 0.97*** (0.95; 0.98) 0.98 (0.96; 0.99) 0.98 (0.97; 0.99) 0.97** (0.95; 0.99) 0.97** (0.96; 0.99) 
Household income 
  < 100,000 CAD$ 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  ≥100,000 CAD$ 0.73* (0.58; 0.91) 0.82 (0.64; 1.05) 0.83 (0.67; 1.03) 0.72 (0.55; 0.95) 1.11 (0.91; 1.35) 
  Prefer not to answer 0.82 (0.59; 1.16) 0.64 (0.42; 0.98) 1.06 (0.77; 1.45) 1.25 (0.87; 1.81) 0.60* (0.42; 0.85) 
Parent’s religion 
  No religious affiliation  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation  1.09 (0.88; 1.36) 0.95 (0.74; 1.22) 0.89 (0.73; 1.10) 0.95 (0.73; 1.22) 0.99 (0.81; 1.21) 
Born in Canada 
  Yes 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  No 1.82*** (1.37; 2.42) 1.55* (1.12; 2.16) 1.51* (1.14; 2.01) 1.37 (0.96; 1.95) 1.26 (0.95; 1.67) 
Child’s school’s religion 
  No affiliation 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation 1.01 (0.80; 1.27) 0.97 (0.74; 1.27) 1.02 (0.82; 1.28) 0.90 (0.68; 1.20) 0.95 (0.76; 1.18) 
Child’s school’s language 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French and other  1.27 (1.03; 1.56) 0.71* (0.54; 0.92) 0.68** (0.55; 0.84) 1.04 (0.81; 1.35) 0.56*** (0.45; 0.69) 
Size of city 
  <100.000 inhabitants 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  ≥100,000 inhabitants 0.93 (0.76; 1.14) 1.17 (0.92; 1.48) 1.24 (1.02; 1.51) 1.00 (0.79; 1.28) 1.27 (1.05; 1.53) 
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Variables Stage 1-Unaware 
OR (95% CI) 
n = 604 
Stage 2-Unengaged 
OR (95% CI) 
n = 395 
Stage 3-Undecided 
OR (95% CI) 
n = 680 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 353 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 786 
Parent’s level of education 
  Elementary or high school 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Trade technical or university 1.10 (0.85; 1.43) 1.17 (0.86; 1.59) 1.23 (0.95; 1.60) 1.00 (0.74; 1.36) 1.45* (1.12; 1.87) 
Parent’s employment status 
  Employed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Not employed  1.00 (0.77; 1.30) 0.77 (0.56; 1.06) 1.09 (0.85; 1.39) 1.35 (1.01; 1.80) 0.98 (0.77; 1.25) 
Marital status 
  Single, separated, divorced, widowed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Married or common law 0.97 (0.76; 1.25) 1.30 (0.96; 1.77) 0.97 (0.76; 1.24) 0.93 (0.69; 1.26) 1.04 (0.82; 1.32) 
Number of children in the family 
  Three or more children  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  One child  1.05 (0.79; 1.38) 0.97 (0.71; 1.34) 1.12 (0.85; 1.47) 0.72 (0.51; 1.00) 0.84 (0.64; 1.09) 
  Two children 0.90 (0.71; 1.14) 0.86 (0.66; 1.13) 1.05 (0.83; 1.33) 0.75 (0.57; 0.99) 1.02 (0.82; 1.27) 
Child’s sexual orientation 
  Heterosexual  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Other sexual orientation 1.26 (0.93; 1.71) 1.17 (0.82; 1.67) 1.16 (0.86; 1.57) 1.33 (0.93; 1.91) 1.13 (0.84; 1.51) 
HPV General knowledge  
(One-unit increase) 
0.87*** (0.85; 0.88) 0.93*** (0.91; 0.95) 0.97** (0.95; 0.99) 1.03* (1.01; 1.06) 1.01 (0.99; 1.03) 
Province with funded HPV vaccination for 
boys 
  No 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
  Yes 0.34*** (0.24; 0.48) 0.49** (0.34; 0.70) 0.50*** (0.37; 0.67) 0.90 (0.66; 1.23) 0.92 (0.72; 1.17) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 961). Bold integers indicates significant OR at p < .05. *p < .01, **p < .001, ***p 
< .0001. (reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval. HCP = health care provider.  
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2. Bivariate and multivariate multinomial logistic regression analyses for parents of boys (n = 1,826) 
 
Additional analyses were conducted to examine the correlates of PAPM stage for parents of boys. Table B2 reports findings 
from the bivariate multinomial logistic regression analysis of parents of boys’ PAPM stage. Table B3 reports findings from the 
multivariate multinomial logistic regression analysis of parents of boys’ PAPM stage. Finally, Table B4 reports on exploratory 
bivariate multinomial logistic regression analyses that were conducted to examine the relationship between additional variables of 
interest and parents of boys’ PAPM stage. 
 
 
Table B2. Bivariate multinomial logistic regression analysis of parents of boys’ PAPM stage (n = 1,826)  
 
Variables Stage 1-Unaware 
OR (95% CI) 
n = 468 
Stage 2-Unengaged 
OR (95% CI) 
n = 298 
Stage 3-Undecided 
OR (95% CI) 
n = 389 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 162 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 349 
Child’s age (One-year increase) 0.77*** (0.71; 0.84) 0.86** (0.79; 0.94) 0.84*** (0.78; 0.92) 0.82** (0.74; 0.91) 0.79*** (0.72; 0.86) 
Language parents answered the 
survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  3.08*** (1.97; 4.82) 1.45 (0.89; 2.36) 1.28 (0.80; 2.06) 1.65 (0.96; 2.83) 0.84 (0.51; 1.39) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 0.82 (0.48; 1.39) 0.81 (0.46; 1.40) 0.94 (0.54; 1.61) 1.21 (0.62; 2.37) 0.83 (0.50; 1.42) 
HCP Recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Yes 0.01 (0.01; 243) 0.07*** (0.03; 0.16) 0.21*** (0.12; 0.35) 0.09*** (0.04; 0.24) 0.46* (0.29; 0.74) 
HPV Vaccine knowledge  
(One-unit increase)  
0.69*** (0.64; 0.74) 0.76*** (0.71; 0.82) 0.86*** (0.80; 0.93) 0.93 (0.85; 1.01) 0.98 (0.90; 1.05) 
Susceptibility (One-unit increase) 0.45*** (0.38; 0.54) 0.40*** (0.33; 0.49) 0.40*** (0.33; 0.48) 0.15*** (0.12; 0.18) 0.96 (0.80; 1.15) 
Severity (One-unit increase) 0.74* (0.61; 0.89) 0.71** (0.58; 0.87) 0.71** (0.58; 0.86) 0.42*** (0.34; 0.52) 1.04 (0.85; 1.28) 
Benefits (One-unit increase) 0.50*** (0.41; 0.62) 0.41*** (0.33; 0.51) 0.39*** (0.31; 0.48) 0.08*** (0.05; 0.10) 1.26 (1.02; 1.56) 
Barriers-Affordability (One-unit 
increase) 
2.56*** (2.23; 2.95) 2.27*** (1.96; 2.62) 2.39*** (2.08; 2.76) 1.50*** (1.28; 1.74) 2.17*** (1.88; 2.50) 
Barriers-Accessibility (One-unit 
increase) 
3.01*** (2.50; 3.63) 2.48*** (2.04; 3.01) 2.26*** (1.88; 2.72) 1.86*** (1.50; 2.30) 1.42** (1.19; 1.70) 
Barriers-Harms (One-unit 
increase) 
2.26*** (1.91; 2.67) 2.46*** (2.06; 2.95) 2.76*** (2.31; 3.29) 8.58***(6.73;10.93) 1.09 (0.92; 1.28) 
Cues to action (One-unit increase) 0.16*** (0.13; 0.21) 0.12*** (0.09; 0.15) 0.13*** (0.10; 0.17) 0.05*** (0.04; 0.06) 0.50*** (0.41; 0.62) 
Self-Efficacy (One-unit increase) 0.52*** (0.42; 0.64) 0.50*** (0.40; 0.63) 0.51*** (0.41; 0.63) 0.94 (0.72; 1.23) 0.96 (0.76; 1.20) 
 9 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 160). Bold integers indicates significant OR at p < .05, *p < .01, **p < .001, ***p 
< .0001. (reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval. HCP = health care provider.  
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Table B3. Multivariate multinomial logistic regression analysis of parents of boys’ PAPM stage (n = 1,826) 
 
Variables  Stage 1-Unaware 
AOR (95% CI) 
n = 468 
Stage 2-Unengaged 
AOR (95% CI) 
n = 298 
Stage 3-Undecided 
AOR (95% CI) 
n = 389 
Stage 4-Decided  
AOR (95% CI) 
n = 162 
Stage 5-Decided 
YES 
AOR (95% CI) 
n= 349 
Child’s age (One-year increase) 0.75*** (0.67; 0.84) 0.84* (0.74; 0.94) 0.82** (0.73; 0.92) 0.88 (0.76; 1.01) 0.74*** (0.66; 0.82) 
Language parents answered the 
survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  1.45 (0.81; 2.61) 0.74 (0.40; 1.37) 0.69 (0.37; 1.26) 0.81 (0.38; 1.73) 0.51 (0.28; 0.92) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 1.16 (0.59; 2.28) 1.20 (0.60; 2.40) 1.39 (0.70; 2.74) 1.17 (0.47; 2.95) 0.84 (0.44; 1.59) 
HCP Recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference)  
 
(reference) 
 
(reference) 
  Yes NA  0.17*** (0.07; 0.44) 0.40 (0.20; 0.81) 0.10* (0.02; 0.43) 0.62 (0.35; 1.10) 
HPV Vaccine knowledge  
(One-unit increase)  
0.81*** (0.74; 0.89) 0.92 (0.84; 1.01) 1.04 (0.95; 1.14) 1.14 (1.01; 1.28) 1.03 (0.94; 1.13) 
Susceptibility (One-unit increase) 0.89 (0.66; 1.21) 0.90 (0.66; 1.22) 0.86 (0.63; 1.16) 0.68 (0.47; 0.99) 1.00 (0.75; 1.34) 
Severity (One-unit increase) 0.99 (0.77; 1.30) 1.01 (0.77; 1.33) 1.01 (0.77; 1.31) 0.60* (0.44; 0.83) 1.04 (0.80; 1.34) 
Benefits (One-unit increase) 1.83* (1.24; 2.71) 1.50 (1.01; 2.23) 1.34 (0.91; 1.98) 0.64 (0.39; 1.03) 2.08*** (1.43; 3.04) 
Barriers-Affordability (One-unit 
increase) 
2.10*** (1.75; 2.51) 1.87*** (1.56; 2.25) 2.05*** (1.71; 2.45) 1.52** (1.21; 1.92) 1.83*** (1.55; 2.15) 
Barriers-Accessibility (One-unit 
increase) 
1.39 (1.08; 1.80) 1.15 (0.88; 1.51) 1.04 (0.81; 1.35) 1.09 (0.77; 1.54) 1.02 (0.80; 1.30) 
Barriers-Harms (One-unit 
increase) 
1.28 (1.01; 1.63) 1.37 (1.07; 1.76) 1.55** (1.22; 1.97) 2.63*** (1.91; 3.62) 0.94 (0.74; 1.18) 
Cues to action (One-unit increase) 0.21*** (0.15; 0.30)  0.15*** (0.11; 0.22) 0.18*** (0.12; 0.25) 0.15*** (0.10; 0.23) 0.35*** (0.25; 0.49) 
Self-Efficacy (One-unit increase) 1.05 (0.75; 1.48) 1.04 (0.73; 1.47) 0.97 (0.69; 1.36) 1.68 (1.13; 2.52) 1.08 (0.76; 1.54) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 160). Bold integers indicates significant AOR at p < .05, *p < .01, **p < .001, ***p 
< .0001; NA when cell size = 0. Cox-Snell R
2
 = 0.60. Cragg Uhler R
2
 = 0.62. McFadden R
2
 = 0.27. (reference) = reference category. AOR = adjusted odds ratio. 
95% CI = 95% confidence interval. HCP = health care provider. 
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Table B4. Bivariate multinomial logistic regression analysis of parents of boys’ PAPM stage (n = 1,826) for additional variables 
 
Variables  Stage 1-Unaware 
OR (95% CI) 
n = 468 
Stage 2-Unengaged 
OR (95% CI) 
n = 298 
Stage 3-Undecided 
OR (95% CI) 
n = 389 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 162 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 349 
Parent’s gender 
  Male 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Female 0.80 (0.55; 1.17) 0.63 (0.42; 0.94) 1.04 (0.71; 1.54) 1.24 (0.78; 1.99) 1.04 (0.70; 1.54) 
Parent’s age (one year increase) 0.96** (0.93; 0.98) 0.97 (0.95; 1.00) 0.98 (0.95; 1.00) 0.95** (0.92; 0.98) 0.97 (0.94; 0.99) 
Household income 
  < 100,000 CAD$ 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  >100,000 CAD$ 0.67 (0.45; 0.99) 0.79 (0.52; 1.20) 0.79 (0.53; 1.18) 0.57 (0.35; 0.93) 1.12 (0.75; 1.67) 
  Prefer not to answer 0.61 (0.35; 1.06) 0.41* (0.21; 0.77) 0.74 (0.42; 1.29) 0.71 (0.37; 1.36) 0.50 (0.27; 0.93) 
Parent’s religion 
  No religious affiliation  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation  1.43 (0.99; 2.08) 1.23 (0.83; 1.83) 1.06 (0.73; 1.54) 1.30 (0.82; 2.05) 1.39 (0.94; 2.05) 
Born in Canada 
  Yes 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  No 1.63 (0.94; 2.81) 1.51 (0.85; 2.70) 1.55 (0.89; 2.72) 1.44 (0.75; 2.76) 1.41 (0.80; 2.50) 
Child’s school’s religion 
  No affiliation 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation 1.24 (0.80; 1.90) 1.29 (0.82; 2.04) 1.25 (0.80; 1.94) 1.18 (0.70; 1.98) 1.39 (0.89; 2.17) 
Child’s school’s language 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French and other  2.86*** (1.86; 4.39) 1.39 (0.87; 2.22) 1.40 (0.90; 2.20) 2.11* (1.28; 3.50) 0.88 (0.55; 1.42) 
Size of city 
  <100.000 inhabitants 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  >100,000 inhabitants 1.03 (0.72; 1.48) 1.38 (0.94; 2.03) 1.26 (0.87; 1.82) 0.95 (0.62; 1.47) 1.32 (0.90; 1.91) 
Parent’s level of education 
  Elementary or high school 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Trade technical or university 0.98 (0.62; 1.57) 1.07 (0.65; 1.77) 1.40 (0.85; 2.30) 0.87 (0.50; 1.51) 1.18 (0.72; 1.94) 
Parent’s employment status 
  Employed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Not employed  0.77 (0.51; 1.18) 0.53 (0.33; 0.86) 0.75 (0.49; 1.16) 0.89 (0.53; 1.48) 0.79 (0.51; 1.23) 
Marital status 
  Single, separated, divorced, 
widowed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Married or common law 0.96 (0.61; 1.49) 1.32 (0.81; 2.16) 0.83 (0.53; 1.29) 0.88 (0.52; 1.49) 1.07 (0.67; 1.71) 
Number of children in the family      
 12 
Variables  Stage 1-Unaware 
OR (95% CI) 
n = 468 
Stage 2-Unengaged 
OR (95% CI) 
n = 298 
Stage 3-Undecided 
OR (95% CI) 
n = 389 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 162 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 349 
  Three or more children  (reference) (reference) (reference) (reference) (reference) 
  One child  1.28 (0.78; 2.11) 1.25 (0.73; 2.13) 1.57 (0.94; 2.63) 0.99 (0.55; 1.82) 1.09 (0.64; 1.86) 
  Two children 0.99 (0.66; 1.49) 0.97 (0.62; 1.50) 1.35 (0.88; 2.06) 0.78 (0.47; 1.28) 1.23 (0.80; 1.87) 
Child’s sexual orientation 
  Heterosexual  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Other sexual orientation 1.12 (0.64; 1.96) 1.08 (0.59; 1.98) 0.80 (0.44; 1.46) 0.86 (0.42; 1.76) 1.02 (0.57; 1.84) 
HPV General knowledge  
(One-unit increase) 
0.87*** (0.84; 0.90) 0.93*** (0.89; 0.96) 0.97 (0.93; 0.99) 1.01 (0.97; 1.05) 1.02 (0.98; 1.05) 
Vaccine conspiracy beliefs (One-
unit increase) 
1.58*** (1.37; 1.82) 1.59*** (1.36; 1.84) 1.59*** (1.37; 1.83) 3.11*** (2.58; 3.74) 1.01 (0.87; 1.17) 
Hesitancy-Lack of Confidence (7 
items) 
(One-unit increase) 
2.35*** (1.71; 3.22) 2.53*** (1.81; 3.54) 2.61*** (1.89; 3.61) 9.01***(6.23; 13.03) 0.83 (0.59; 1.16) 
Hesitancy-Risks (2 items)  
(One-unit increase) 
1.93*** (1.58; 2.36) 1.91*** (1.54; 2.37) 2.38*** (1.92; 2.93) 5.06*** (3.83; 6.68) 1.12 (0.91; 1.37) 
Province with funded HPV 
vaccination for boys 
  No 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
  Yes 0.09*** (0.05; 0.15) 0.16*** (0.10; 0.26) 0.10*** (0.06; 0.17) 0.35*** (0.21; 0.57) 0.39*** (0.26; 0.59) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 160). Bold integers indicates significant OR at p < .05, *p < .01, **p < .001, ***p 
< .0001. (reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval.  
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3. Bivariate and multivariate multinomial logistic regression analyses for parents of girls (n = 1,953) 
 
Additional analyses were conducted to examine the correlates of PAPM stage for parents of girls. Table B5 reports findings 
from the bivariate multinomial logistic regression analysis of parents of girls’ PAPM stage. Table B6 reports findings from the 
multivariate multinomial logistic regression analysis of parents of girls’ PAPM stage. Finally, Table B7 reports on exploratory 
bivariate multinomial logistic regression analyses that were conducted to examine the relationship between additional variables of 
interest and parents of girls’ PAPM stage. 
 
Table B5. Bivariate multinomial logistic regression analysis of parents of girls’ PAPM stage (n = 1,953) 
 
Variables  Stage 1-Unaware 
OR (95% CI) 
n = 136 
Stage 2-Unengaged 
OR (95% CI) 
n = 97 
Stage 3-Undecided 
OR (95% CI) 
n = 291 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 191 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 437 
Child’s age (One-year increase) 0.62*** (0.57; 0.68) 0.65*** (0.59; 0.72) 0.66*** (0.62; 0.70) 0.80*** (0.74; 0.86) 0.65*** (0.62; 0.69) 
Language parents answered the 
survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  0.63 (0.42; 0.96) 0.48* (0.29; 0.81) 0.45*** (0.32; 0.63) 0.84 (0.60; 1.19) 0.48*** (0.36; 0.63) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 0.45** (0.29; 0.72) 0.41** (0.25; 0.69) 0.65 (0.44; 0.95) 0.78 (0.49; 1.24) 0.68 (0.49; 0.96) 
HCP Recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Yes 0.06*** (0.01; 0.24) 0.08** (0.02; 0.34) 0.42*** (0.28; 0.65) 0.77 (0.51; 1.17) 0.92 (0.68; 1.23) 
HPV Vaccine knowledge  
(One-unit increase)  
0.58*** (0.54; 0.62) 0.69*** (0.64; 0.74) 0.80*** (0.76; 0.84) 1.01 (0.94; 1.09) 0.91** (0.87; 0.96) 
Susceptibility (One-unit increase) 0.50*** (0.43; 0.59) 0.50*** (0.42; 0.60) 0.40*** (0.36; 0.46) 0.18*** (0.15; 0.21) 1.04 (0.93; 1.16) 
Severity (One-unit increase) 0.74** (0.62; 0.87) 0.75* (0.62; 0.91) 0.77*** (0.68; 0.88) 0.54*** (0.47; 0.62) 1.00 (0.88; 1.13) 
Benefits (One-unit increase) 0.50*** (0.40; 0.61) 0.51*** (0.40; 0.64) 0.33*** (0.28; 0.39) 0.08*** (0.06; 0.10) 1.32*** (1.15; 1.50) 
Barriers-Affordability (One-unit 
increase) 
2.91*** (2.52; 3.37) 2.13*** (1.82; 2.49) 1.98*** (1.79; 2.20) 1.25** (1.10; 1.41) 1.77*** (1.62; 1.95) 
Barriers-Accessibility (One-unit 
increase) 
3.60*** (2.96; 4.37) 2.75*** (2.23; 3.40) 2.39*** (2.08; 2.74) 1.74*** (1.49; 2.03) 1.53*** (1.36; 1.72) 
Barriers-Harms (One-unit 
increase) 
2.38*** (2.01; 2.82) 2.34*** (1.94; 2.84) 3.84*** (3.30; 4.47) 9.64***(7.74;12.00) 1.20** (1.08; 1.33) 
Cues to action (One-unit increase) 0.17*** (0.13; 0.22) 0.15*** (0.12; 0.20) 0.15*** (0.12; 0.19) 0.08*** (0.06; 0.10) 0.67*** (0.58; 0.76) 
Self-Efficacy (One-unit increase) 0.42*** (0.36; 0.50) 0.50*** (0.41; 0.62) 0.52*** (0.45; 0.60) 1.09 (0.90; 1.33) 1.01 (0.87; 1.16) 
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Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 801). Bold integers indicates OR at p < .05, *p < .01, **p < .001, ***p < .0001. 
(reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval. HCP = health care provider. 
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Table B6. Multivariate multinomial logistic regression analysis of parents of girls’ PAPM stage (n = 1,953) 
 
Variables  Stage 1-Unaware 
AOR (95% CI) 
n = 136 
Stage 2-Unengaged 
AOR (95% CI) 
n = 97 
Stage 3-Undecided 
AOR (95% CI) 
n = 291 
Stage 4-Decided 
NOT 
AOR (95% CI) 
n = 191 
Stage 5-Decided YES 
AOR (95% CI) 
n= 437 
Child’s age (One-year increase) 0.54*** (0.48; 0.60) 0.61*** (0.55; 0.69) 0.62*** (0.57; 0.67) 0.82* (0.72; 0.93) 0.60*** (0.56; 0.64) 
Language parents answered the 
survey 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French  0.80 (0.45; 1.40) 0.57 (0.31; 1.05) 0.62** (0.30; 0.74) 0.82 (0.51; 1.79) 0.60*** (0.33; 0.65) 
Parent’s ethnicity 
  Other 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  White 1.48 (0.80; 2.75) 1.11 (0.59; 2.07) 1.76 (1.06; 2.93) 0.96 (0.44; 2.10) 1.75* (1.15; 2.67) 
HCP Recommendation 
  No 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Yes 0.11* (0.02; 0.50) 0.15 (0.04; 0.66) 0.56 (0.32; 0.98) 0.39 (0.17; 0.91) 0.92 (0.65; 1.32) 
HPV Vaccine knowledge  
(One-unit increase)  
0.68*** (0.62; 0.75) 0.81*** (0.74; 0.89) 0.96 (0.89; 1.03) 1.16 (1.03; 1.30) 0.92* (0.87; 0.98) 
Susceptibility (One-unit increase) 1.13 (0.82; 1.55) 1.08 (0.79; 1.48) 0.88 (0.71; 1.10) 0.64* (0.49; 0.85) 1.08 (0.90; 1.30) 
Severity (One-unit increase) 1.20 (0.93; 1.56) 1.08 (0.83; 1.41) 1.10 (0.90; 1.34) 0.68* (0.52; 0.89) 0.99 (0.84; 1.17) 
Benefits (One-unit increase) 1.97* (1.30; 2.97) 1.91* (1.25; 2.91) 1.45 (1.08; 1.96) 0.56* (0.38; 0.84) 2.18*** (1.72; 2.76) 
Barriers-Affordability (One-unit 
increase) 
2.35*** (1.90; 2.91) 1.48** (1.19; 1.83) 1.45*** (1.24; 1.70) 0.97 (0.75; 1.26) 1.65*** (1.46; 1.86) 
Barriers-Accessibility (One-unit 
increase) 
1.61* (1.20; 2.16) 1.49 (1.10; 2.01) 1.17 (0.93; 1.46) 1.08 (0.77; 1.52) 1.27* (1.07; 1.52) 
Barriers-Harms (One-unit 
increase) 
1.34 (1.03; 1.74) 1.60** (1.23; 2.08) 2.82*** (2.33; 3.42) 4.05*** (3.05; 5.38) 1.20 (1.03; 1.39)  
Cues to action (One-unit increase) 0.30*** (0.21; 0.44) 0.21*** (0.14; 0.30) 0.27*** (0.21; 0.36) 0.24*** (0.16; 0.35) 0.62*** (0.50; 0.76) 
Self-Efficacy (One-unit increase) 0.87 (0.66; 1.16) 1.15 (0.86; 1.53) 1.12 (0.90; 1.39) 1.86*** (1.38; 2.50) 1.26 (1.01; 1.56) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 801). Bold integers indicates significant AOR at p < .05, *p < .01, **p < .001, ***p 
< .0001. Cox-Snell R
2
 = 0.71. Cragg Uhler R
2
 = 0.75. McFadden R
2
 = 0.41. (reference) = reference category. AOR = adjusted odds ratio. 95% CI = 95% 
confidence interval. HCP = health care provider. 
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Table B7. Bivariate multinomial logistic regression analysis of parents of girls’ PAPM stage (n = 1,953) for additional variables 
 
Variables  Stage 1-Unaware 
OR (95% CI) 
n = 136 
Stage 2-Unengaged 
OR (95% CI) 
n = 97 
Stage 3-Undecided 
OR (95% CI) 
n = 291 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 191 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 437 
Parent’s gender 
  Male 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Female 0.37*** (0.26; 0.54) 0.40*** (0.26; 0.61) 0.74 (0.56; 0.98) 1.53 (1.05; 2.24) 0.80 (0.62; 1.03) 
Parent’s age (one year increase) 0.96* (0.93; 0.99) 0.96* (0.93; 0.99) 0.97* (0.95; 0.99) 0.98 (0.95; 1.00) 0.97** (0.95; 0.98) 
Household income 
  < 100,000 CAD$ 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  >100,000 CAD$ 0.61 (0.41; 0.91) 0.58 (0.36; 0.94) 0.76 (0.56; 1.02) 0.80 (0.56; 1.14) 1.02 (0.80; 1.30) 
  Prefer not to answer 0.62 (0.32; 1.22) 0.80 (0.39; 1.63) 1.11 (0.73; 1.71) 1.57 (0.99; 2.50) 0.54 (0.34; 0.87) 
Parent’s religion 
  No religious affiliation  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation  0.97 (0.66; 1.43) 0.89 (0.57; 1.39) 0.95 (0.71; 1.26) 0.85 (0.61; 1.18) 0.87 (0.68; 1.12) 
Born in Canada 
  Yes 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  No 2.67*** (1.72; 4.15) 1.76 (1.01; 3.06) 1.48 (1.01; 2.17) 1.32 (0.84; 2.09) 1.16 (0.81; 1.65) 
Child’s school’s religion 
  No affiliation 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Any religious affiliation 1.11 (0.99; 1.02) 0.81 (1.01; 1.03) 1.05 (0.99; 1.02) 0.85 (1.00; 1.02) 0.81 (0.99; 1.01) 
Child’s school’s language 
  English 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  French and other  0.76 (0.51; 1.12) 0.68 (0.42; 1.08) 0.59** (0.43; 0.79) 0.93 (0.66; 1.29) 0.59*** (0.45; 0.76) 
Size of city 
  <100.000 inhabitants 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  >100,000 inhabitants 0.78 (0.54; 1.12) 0.82 (0.54; 1.25) 1.29 (0.99; 1.69) 1.09 (0.79; 1.49) 1.27 (1.01; 1.61) 
Parent’s level of education 
  Elementary or high school 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Trade technical or university 1.22 (0.75; 1.97) 1.17 (0.67; 2.02) 0.97 (0.70; 1.36) 1.07 (0.71; 1.59) 1.62* (1.17; 2.24) 
Parent’s employment status 
  Employed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Not employed  0.71 (0.42; 1.21) 0.86 (0.48; 1.53) 1.19 (0.85; 1.67) 1.53 (1.05; 2.23) 0.94 (0.69; 1.28) 
Marital status 
  Single, separated, divorced,     
widowed 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Married or common law 1.08 (0.68; 1.71) 1.29 (0.74; 2.27) 1.26 (0.89; 1.79) 1.00 (0.67; 1.47) 1.03 (0.77; 1.38) 
Number of children in the family      
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Variables  Stage 1-Unaware 
OR (95% CI) 
n = 136 
Stage 2-Unengaged 
OR (95% CI) 
n = 97 
Stage 3-Undecided 
OR (95% CI) 
n = 291 
Stage 4-Decided 
NOT 
OR (95% CI) 
n = 191 
Stage 5-Decided 
YES 
OR (95% CI) 
n= 437 
  Three or more children  (reference) (reference) (reference) (reference) (reference) 
  One child  1.36 (0.82; 2.24) 1.04 (0.58; 1.86) 0.99 (0.69; 1.43) 0.65 (0.42; 1.02) 0.81 (0.58; 1.12) 
  Two children 1.16 (0.74; 1.81) 0.99 (0.60; 1.63) 0.91 (0.67; 1.25) 0.81 (0.56; 1.15) 0.98 (0.75; 1.29) 
Child’s sexual orientation 
  Heterosexual  
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
 
(reference) 
  Other sexual orientation 1.78 (1.09; 2.89) 1.45 (0.80; 2.61) 1.68* (1.16; 2.44) 1.77* (1.16; 2.72) 1.21 (0.85; 1.72) 
HPV General knowledge  
(One-unit increase) 
0.82*** (0.79; 0.85) 0.89*** (0.86; 0.92) 0.96** (0.93; 0.98) 1.04* (1.01; 1.08) 1.00 (0.98; 1.03) 
Vaccine conspiracy beliefs (One-
unit increase) 
1.69*** (1.47; 1.95) 1.47*** (1.25; 1.72) 1.80*** (1.61; 2.01) 3.34*** (2.87; 3.89) 0.97 (0.89; 1.06) 
Hesitancy-Lack of Confidence (7 
items) 
(One-unit increase) 
2.87*** (2.13; 3.86) 2.86*** (2.04; 4.01) 3.51*** (2.79; 4.42) 10.22***(7.74;13.50) 0.92 (0.74; 1.14) 
Hesitancy-Risks (2 items) (One-
unit increase) 
1.79*** (1.44; 2.22) 1.66*** (1.29; 2.12) 2.74*** (2.30; 3.27) 6.09*** (4.80; 7.73) 1.02 (0.90; 1.16) 
Province with funded HPV 
vaccination for boys  
  No 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
 
 
(reference) 
  Yes 0.90 (0.54; 1.52) 0.86 (0.47; 1.59) 1.07 (0.74; 1.55) 1.12 (0.73; 1.71) 1.04 (0.76; 1.44) 
Note. The reference category for PAPM stage is ‘Stage 6-Vaccinated’ (n = 801). Bold integers indicates significant odds ratio (OR) at p < .05, *p < .01, **p 
< .001, ***p < .0001. (reference) = reference category. OR = odds ratio. 95% CI = 95% confidence interval.  
 
 
